Journal
PEDIATRIC BLOOD & CANCER
Volume 50, Issue 2, Pages 201-207Publisher
WILEY
DOI: 10.1002/pbc.21280
Keywords
cefixime; cefpodoxime; diarrhea; irinotecan
Categories
Ask authors/readers for more resources
Irinotecan is increasingly being used in pediatric oncology. Amelioration of diarrhea associated with protracted irinotecan administration may reduce morbidity and improve dose intensity. In this review, we discuss what is known about the pathogenesis of this toxicity as well as potential predisposing genetic factors. We comprehensively summarize the literature regarding available prevention and treatment strategies, and report data on the use of cephalosporin prophylaxis in 51 patients treated on various pediatric trials. This approach is feasible in children and allows for tolerance of higher doses of protracted irinotecan.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available